The folate receptor β as a macrophage-mediated imaging and therapeutic target in rheumatoid arthritis

Durga M. S. H. Chandrupatla 1 · Carla F. M. Molthoff 2 · Adriaan A. Lammertsma 2 · Conny J. van der Laken 1 · Gerrit Jansen 1

Published online: 2 October 2018 © The Author(s) 2018

Abstract
Macrophages play a key role in the pathophysiology of rheumatoid arthritis (RA). Notably, positive correlations have been reported between synovial macrophage infiltration and disease activity as well as therapy outcome in RA patients. Hence, macrophages can serve as an important target for both imaging disease activity and drug delivery in RA. Folate receptor β (FRβ) is a glycosylphosphatidylinositol (GPI)-anchored plasma membrane protein being expressed on myeloid cells and activated macrophages. FRβ harbors a nanomolar binding affinity for folic acid allowing this receptor to be exploited for RA disease imaging (e.g., folate-conjugated PET tracers) and therapeutic targeting (e.g., folate antagonists and folate-conjugated drugs). This review provides an overview of these emerging applications in RA by summarizing and discussing properties of FRβ, expression of FRβ in relation to macrophage polarization, FRβ-targeted in vivo imaging modalities, and FRβ-directed drug targeting.

Keywords Rheumatoid arthritis · Macrophages · Folate receptor · Folate-conjugated drugs · Imaging · Positron emission tomography (PET)

Rheumatoid arthritis
Rheumatoid arthritis (RA) is an autoimmune disease, which affects approximately 0.5–1.0% of the world population [1]. Although the exact etiology of RA is unknown, the currently accepted hypothesis consists of two stages [2]. In genetically susceptible individuals, the first stage of development of RA consists of accelerated citrullination of proteins in extra-articular sites, e.g., due to smoking or infection, including formation of rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPA), and anti-carbamylated proteins (a-CarbP) [3–6]. Only 40% of ACPA-positive arthralgia individuals will eventually develop RA [7]. A second trigger seems to be needed for development of clinical disease. Up to 15 years later, the second trigger could be an unrelated episode of otherwise self-limiting synovial inflammation and associated locally induced citrullination. In the presence of pre-existing anti-citrullinated protein/peptide antibodies, this event may induce chronic synovitis evolving into clinical RA through binding of the antibodies to autoantigens in the joints [8–10] (Fig. 1).

To detect development of (subclinical) synovitis, advanced imaging techniques may have diagnostic value on top of detection of ACPA. Application of ultrasonography and MRI techniques in preclinical RA have been discussed in recent reports [11, 12], while application of positron emission tomography (PET) will be discussed in detail below. RA’s main characteristics include (chronic) inflamed synovium and joint destruction, which, when left untreated, can lead to permanent joint deformities and comorbidities, such as cardiovascular disease and osteoporosis [10]. Early identification and treatment of RA is currently recommended to prevent further joint damage and disability [13]. To this end, the European League Against Rheumatism (EULAR) guidelines indicate treatment with classical disease-modifying anti-rheumatic drugs (DMARDs) (e.g., methotrexate (MTX)), biological DMARDs (e.g., infliximab, rituximab, tocilizumab, and secukinumab), and targeted synthetic DMARDs (e.g., Janus
In RA, the inflamed synovium harbors several immune cell types, especially B and T lymphocytes, dendritic cells, neutrophils, and macrophages [8–10] (Fig. 2a). As dominant producers of tumor necrosis factor alpha (TNFα), macrophages are known to play a central role in RA disease progression [15–19], macrophage production of IL1β, IL-6, and TNFα mediates proliferation and activation of fibroblast-like synoviocytes [20]. These promote formation and activation of osteoclasts and chondrocytes, which drive bone and cartilage destruction [8–10, 18, 20], being hallmarks of RA disease (Fig. 2a). Cytokine networks involving a.o. IL15, IL17, IL18, IL21, IL23, and IFNγ mediate interactions among macrophages and B cells, T cells, and dendritic cells to induce pro-inflammatory effects (reviewed in [8, 9, 21, 22]). For example, IL17 release by T cells triggers activation of synovial fibroblasts and osteoclasts [8, 21], whereas B cells/plasma cells primarily release autoantibodies such as rheumatoid factor and ACPAs to promote T cell activation [23, 24]. Macrophages in inflamed synovium are thought to be mainly derived from influx of circulating monocytes [16, 17] (Fig. 2b). Following differentiation of monocytes into macrophages, various cytokines and immune complexes can skew them in subcategories designed M1-type (pro-inflammatory) and M2-type (anti-inflammatory) macrophages, featuring characteristic cluster of differentiation (CD) membrane marker expression and release of cytokines, chemokines, and degrading enzymes [18, 19] (Fig. 2b). M1-type and M2-type macrophages do not represent static states as in an RA synovial microenvironment; M2-type macrophages can acquire M1-type properties of producing pro-inflammatory cytokines like TNFα, IL1β, and IL-6 [15–27]. Folate receptor β (FRβ) has been identified as an emerging macrophage marker. FRβ properties and clinical exploitation will be discussed in more detail in the following sections. Together, given the prominent role of macrophages in RA pathophysiology, their non-invasive visualization can hold promise for early RA disease monitoring.

**Macrophage PET imaging in RA**

In RA, synovial macrophage infiltration is a hallmark of the disease, reflecting disease activity in early and established stages, being a sensitive biomarker for assessment of response to therapy [28–30]. Therefore, macrophage imaging could serve as an important clinical and diagnostic tool as well as a tool for guiding therapy in RA. Positron emission tomography (PET) is a non-invasive, in vivo imaging modality, with high sensitivity to detect active arthritis both at early or advanced stages of RA [31, 32]. It also has the ability to quantify tracer uptake, which is essential for intervention studies, i.e., for monitoring disease activity and therapy response in the
While ultrasound and MRI cover mostly detection of anatomical changes in synovial tissue [37], PET imaging allows for quantitative detection and monitoring of molecular targets. Various PET tracers have been developed to image RA. Initial macrophage-directed PET studies used $[^{18}F]_{\text{FDG}}$ (measuring glucose metabolism in inflammatory sites) to visualize inflamed RA joints with results corresponding to clinical findings, thus providing evidence for the usefulness of PET in detecting synovitis [38–40]. This tracer showed high sensitivity, but low specificity for arthritis imaging [38]. Subsequently, PET studies were extended by using more macrophage-specific tracers (Table 1).

The first class of potential macrophage tracers was targeted towards the 18-kDa translocator protein (TSPO, formerly known as peripheral benzodiazepine receptor), an outer mitochondrial membrane protein that is upregulated in activated macrophages [51, 52]. ($R$)-$[^{11}C]_{\text{PK11195}}$ is the prototypical TSPO tracer that was employed in preclinical RA models [41, 42, 53–56] after successful application for imaging of activated microglia in neuroinflammatory diseases (reviewed in [57, 58]). In a clinical setting, significantly higher ($R$)-$[^{11}C]_{\text{PK11195}}$ uptake was observed in severely inflamed joints of RA patients than in moderately or mildly inflamed joints, which correlated with the extent of macrophage infiltration in excised synovial tissue [43]. In addition, subclinical disease activity could be shown when contralateral uninflamed knee joints of RA were compared with non-inflamed joints of healthy controls [43]. However, ($R$)-$[^{11}C]_{\text{PK11195}}$ showed limitations in detecting subclinical synovitis in RA. In particular, considerable background uptake was seen in periarticular...
tissue both in a rat model of arthritis [48] and in RA patients [35]. To overcome these limitations, a second generation of TSPO tracers was developed, with [11C]DPA713 and [18F]DPA714 [50, 51] having been evaluated in preclinical RA models [42, 59]. Herein, both [11C]DPA713 and [18F]DPA714 were superior to (R)-[11C]PK11195, but this still needs to be confirmed in a clinical setting.

In search for novel macrophage PET tracers in RA, macrophage markers identified on activated microglia can be helpful, e.g., CB2R and A2AR (G protein-coupled receptors), P2X7R (purinergic ion channel receptor), or matrix metalloproteinases [60].

The focus of the present review is on another emerging (activated) macrophage marker, i.e., the folate receptor β (FRβ), which potentially could also be exploited for imaging and therapeutic targeting purposes in RA [61, 62].

### Folate receptors (general properties)

Folate receptors (FR) belong to a family of two other proteins, i.e., reduced folate carrier (RFC) and proton-coupled folate transporter (PCFT). RFC and PCFT have an established function in membrane transport/internalization of folates required for a variety of biosynthetic reactions and DNA synthesis [63–66] (Table 2).

FR, RFC, and PCFT differ in membrane orientation, folate substrate affinity, pH optimum, and tissue distribution [63, 66–68] (Table 2). While RFC and PCFT are transmembrane carrier proteins, FR is anchored to the plasma membrane via a glycosylphosphatidylinositol (GPI) anchor [69]. At least 3 isoforms of FR exist, FRα, FRβ, and FRγ, of which the latter is a soluble secreted form because it lacks a GPI-anchoring signal [70]. FRα and FRβ display high binding affinity for folic acid (Kd 0.1–1.0 nM), but low binding affinity for the folate antagonist methotrexate (MTX) [63, 68, 71, 72]. FRs internalize their substrates via a process of receptor-mediated endocytosis [73, 74] or potocytosis [75]. FRα has a relatively broad tissue distribution profile in normal cells (e.g., kidney) and cancer cells (e.g., ovarian carcinoma cells) [76], whereas FRβ expression is restricted to hematopoietic cells of the myeloid lineage [77, 78]. In fact, FRβ is expressed on monocytes [79], activated macrophages of RA patients [80, 81], tumor-associated macrophages [82], and acute myeloid leukemia (AML) cells [83]. A number of substances have been reported to upregulate FRβ expression, e.g., retinoic acid [84] and curcumin [85], whereas a pluripotent growth factor like activin A downregulates FRβ expression [86].

Given the fact that RFC is constitutively expressed on immune cells [87, 88], including macrophages [86, 89], and exhibits a much greater folate transport capacity than FRβ [68, 81], it is still an unresolved issue whether the primary function of FRβ in macrophages is folate transport rather than other homeostatic or immune-regulatory functions. In rapidly proliferating cancer cells, folate transporters (Table 2) facilitate folate uptake to promote DNA synthesis [66–68]. However, in inflamed RA synovium, increased numbers of macrophages are mainly derived from influx of circulating monocytes (Fig. 2b) following enhanced myelopoiesis [16]. Moreover, RA synovium macrophages display only modest cell proliferation [90, 91], thus suggesting a role for FRβ in folate uptake for macrophage proliferation may not be of primary importance. In this regard, alternative functions for FRβ have been suggested, although they still lack experimental evidence: (a) delivery of folates for biotin metabolism, which facilitates reactive oxygen species (ROS) production in macrophages [92]; (b) FRβ-mediated scavenging of folates from sites of inflammation to deprive pathogens from nutrients [80]; or (c) involvement in signaling processes consistent with the notion that FR, as GPI-anchored protein, is localized in specialized cholesterol-rich membrane invaginations called caveolae, which harbor multiple proteins involved in signaling processes [63, 66]. With respect to the latter, a recent study reported that FRβ on macrophages had a functional interaction with CD11/CD18 to regulate cellular adhesion to collagen [93].

Beyond RA synovium, FRβ expression has been identified on macrophages in inflamed atherosclerotic lesions [94–97], accounting for cardiovascular comorbidities in RA, and tumor-associated macrophages [82, 98–100], thus underscoring that FRβ plays a role on macrophages regulating inflammatory processes. Lastly, in mice, FRβ expression has

---

**Table 1** PET tracers for macrophage imaging in rheumatoid arthritis

| Name                  | PET isotope | Half-life (min) | Binding target | Use                                    | Reference |
|-----------------------|-------------|----------------|----------------|----------------------------------------|-----------|
| FDG                   | 18F         | 110            | Glucose transporter | Glucose metabolism | [39, 40]  |
| (R)-PK11195           | 11C         | 20             | TSPO           | Neuro-inflammation/RA                  | [41–44]  |
| DPA713                | 11C         | 20             | TSPO           | Neuro-inflammation/RA                  | [42, 45]  |
| DPA714                | 18F         | 110            | TSPO           | Neuro-inflammation/RA                  | [42, 46, 47] |
| PEG-Folate receptor   | 18F         | 110            | Folate receptor | RA, arthrosclerosis                   | [48–50]  |
been noted on LyC6 myeloid-derived suppressor cells (MDSC), a myeloid subset capable of suppressing T cell activity [101]. So far, expression of FRβ on human MDSC counterparts has not been examined.

Role of folate receptor β in rheumatoid arthritis

Consistent with FRβ being expressed in hematopoietic cells of the myeloid lineage [77, 78], peripheral blood monocytes (PBMs) from healthy donors and RA patients express FRβ. Based on their CD14/CD16 expression, 3 subclasses of PBMs were identified, classical (CD14+/CD16−), non-classical (CD14−/CD16+) and intermediate (CD14+/CD16+) monocytes, of which the pro-inflammatory classical monocytes expressed FRβ and were capable of binding folate-linked molecules [79]. This finding provides a rationale for targeting pro-inflammatory FRβ+ monocytes to suppress their infiltration into sites of inflammation, e.g., RA synovium [79].

FRβ-positive macrophages were originally identified in RA synovial fluid and assigned a functional role in methotrexate transport [102]. A study by van der Heijden et al. [81] showed that FRβ mRNA expression in synovial fluid macrophages and synovial tissue from RA patients was two orders of magnitude higher than that of T cells from the same patient. Immunohistochemical evaluation of synovial biopsies from RA patients confirmed strong FRβ staining of CD68-positive macrophages both in synovial lining and sublining [81]. Importantly, a study by Xia et al. [80] revealed that especially activated macrophages rather than quiescent macrophages, in RA synovial fluid, had high FRβ expression and concomitant folate conjugate binding activity.

Macrophage FRβ expression is not only restricted to RA, but has also been reported in other arthritis-related diseases. In temporal artery biopsies of giant cell arteritis patients, severe inflammation coincided with FRβ-positive macrophages in the adventitia [103]. In two murine models of systemic lupus erythematosus, the number of FRβ-positive macrophages correlated with disease activity [104]. Also, in two experimental models of autoimmune uveitis and autoimmune encephalomyelitis in rats, FRβ-positive macrophages were detected at local and systemic sites (e.g., peritoneal cavity) of inflammation [105]. Lastly, several studies reported the presence of FRβ on macrophages in knee sections of osteoarthritis patients [106, 107].

Folate receptor β and macrophage polarization

Macrophage heterogeneity is a common feature in RA-inflamed synovial tissue [16–19]. Microenvironmental factors may affect both activation status and skewing of macrophages into various subsets with distinct immunophenotypes and specialized immune-regulatory and homeostatic functions. Polarization of macrophages covers the broad spectrum from pro-inflammatory to anti-inflammatory macrophages, which have been designated “M1-type” (classical activation, pro-inflammatory) macrophages and “M2-type” (alternatively activated, anti-inflammatory) macrophages, respectively [108]. Whereas M1- and M2-type macrophages represent the extremes of polarization, macrophages harbor plasticity of skewing in either direction. There are many markers that may help to differentiate M1/M2 macrophages. M1 macrophages are involved in tumor inhibition and are resistant to pathogens, whereas M2 macrophages promote tumor growth and have immunoregulatory properties [109]. Classical activation stimuli for M1-type macrophages include IFNy, LPS, and GM-CSF; those for M2-type macrophages include M-CSF, IL-4, IL-10, IL13, glucocorticoids, and immune complexes [110, 111]. Immunophenotypically, M1-stimulated macrophages display increased cell surface expression of CD80 (provides a costimulatory signal necessary for T cell activation and survival) and CD64 (Fc-gamma receptor 1, FcγRI), while M2-stimulated macrophages have increased...
expression of CD163 (hemoglobin scavenger receptor), CD206 (mannose receptor), CD200R (orexin receptor 2), and CD32 (FcγRIIa) [112]. CD68 is acknowledged as one of the most common markers for identifying human macrophages [112], although its expression can also be detected on fibroblasts [113]. CD169 (Siglec-1) is a macrophage marker that is implicated in immune tolerance and antigen presentation [114]. Although CD169 has been found on activated macrophages in inflammatory diseases [115, 116], its function in RA is still unknown.

During the past decade, several studies have explored FRβ expression in the context of macrophage polarization. Initially, studies from Puig-Kroger et al. [117] showed that FRβ was preferentially expressed on M2-type macrophages following in vitro skewing of monocytes with M-CSF compared with M1-type macrophages with GM-CSF. Moreover, RA synovial fluid macrophages showed an activin A-dependent skewing to pro-inflammatory M1 macrophages and reduced expression of FRβ [118]. In synovial tissue of osteoarthritis patients, however, FRβ expression was not exclusively observed on either M1- or M2-type macrophages [119]. Some recent studies add complexity to this issue by reporting that M-CSF-polarized FRβ-expressing M2 macrophages demonstrated a high pro-inflammatory response to TLR ligands and complex IgG and/or autoantibodies to citrullinated protein immune complexes (ACPA-IC) as commonly present in RA [25, 26]. Together, these data suggest that FRβ is differentially expressed on in vitro M-CSF skewed M2-type monocyte-derived macrophages, which is in line with FRβ expression on tumor-associated macrophages [82, 99, 100]. However, in RA (and OA) synovium, inflammatory conditions alter macrophage phenotypes along with FRβ expression (Fig. 2b).

**Imaging folate receptor β in rheumatoid arthritis**

The high binding affinity of folate receptors for folic acid has been exploited for the design of multiple imaging agents [120] to either detect FRx expression in tumors [121, 122] and FRβ-expressing macrophages in RA [62, 123]. Subsequently, macrophage FRβ imaging has also been applied in macrophage implicated inflammation-related diseases, e.g., asthma [124–126] and cardiovascular diseases [94, 97]. The first folate macrophage imaging study in rats with adjuvant-induced arthritis was performed using [99mTc]folic acid to generate the single-photon emitting tracer [99mTc]EC20, which enabled visualization of arthritic joints in a rat model [127]. Isolated macrophages from the arthritic rats also showed high FR binding capacity for folate-FITC [127]. Subsequently, [99mTc]EC20 was successfully used to assess disease activity in RA patients with established disease [128, 129] as well as OA patients [107]. In RA patients, the [99mTc]EC20 distribution corresponded with clinical predictors of disease activity [128]. Notably, in a subset of RA patients, [99mTc]EC20 scans detected actively involved joints more accurately than clinical assessments of arthritis [128].

Further development of folate imaging agents also focused on PET tracers, which could be used for detection of (sub)clinical arthritis as well as for more accurate therapy monitoring. To this end, a folate PET tracer, [18F]-fluoro-PEG-folate, was synthesized in a two-step procedure and evaluated in an antigen-induced arthritis model in rats [48]. Uptake of [18F]-fluoro-PEG-folate was significantly higher in arthritic than in non-inflamed control knees, and also arthritic knee to bone and arthritic knee to blood ratios were higher for [18F]-fluoro-PEG-folate than (R)-[11C]PK11195 [48]. In addition, using [18F]-fluoro-PEG-folate PET, it was possible to monitor therapeutic effects of MTX in arthritic rats [49] and to monitor systemic inflammatory effects in an arthritic rat model [50]. Based on these encouraging preclinical results, [18F]-fluoro-PEG-folate was taken to a clinical setting in which this tracer could readily visualize arthritic joints in RA patients [130]. Recently, a novel folate-based PET tracer was synthesized in a faster (<1 h) one-step procedure, i.e., [18F]-folate-PET NOTA-Al [131], which warrants further preclinical evaluation.

Next to folate PET imaging agents, recent progress has been made in the development of folate conjugates of (near infrared) fluorescent probes that can be used for fluorescent and optical imaging purposes [58, 132, 133]. Thus far, these approaches have mostly been applied in a cancer research setting for fluorescence-guided surgery of FRα-positive tumors [134] or macrophage FRβ expression in tumors [135]. Recently, OTL-38, a novel near-infrared fluorescent folate-conjugated imaging agent, showed feasibility of imaging FRα-positive tumors [136]. OTL-38 was also examined in animal models of various inflammatory diseases including RA [137]. Interestingly, the uptake of OLT-38 in inflamed joints of the animals was shown to precede changes in clinical symptoms [137]. However, it should be noted that optical techniques have their limitations. Firstly, the penetrating power of near-infrared light is limited, so that only relatively superficial processes can be imaged. In other words, although imaging in small laboratory animals is possible, translation to the human is difficult and restricted to intraoperative imaging and possibly small hand/foot joints in RA. Secondly, as the amount of light collected by a probe depends on the depth of the source (e.g., tumor) within the body, quantification is very difficult and awaits further developments. Therefore, at this stage, optical imaging is less suited for monitoring quantitative follow-up of therapeutic interventions in vivo in humans.

**Therapeutic targeting of folate receptor β in rheumatoid arthritis**

FRs have not only been exploited for imaging, but also for therapeutic targeting in cancer and inflammation [65, 66].
Targeting of FRα-expressing tumors has included folate-conjugated (α) radionuclides (α-emitters) for cancer treatment; (b) anti-cancer drugs; (c) nanoparticles containing either anti-cancer drugs, siRNAs, miRNAs, or genes; or (d) folate antagonists for which FRα has a high affinity [65, 68, 138].

For FRβ, similar targeting approaches are applicable [139]. Table 3 provides a selection of approaches that have been reported for targeting FRβ-expressing macrophages in RA and RA-related diseases as well as for FRβ-expressing tumor-associated macrophages and FRβ-expressing acute myeloid leukemia cells. Conceivably, applications in the cancer setting may be translatable to the RA setting. Table 3 describes several modalities for FRβ targeting, including folate antagonists, folate-conjugated immunotoxins, folate-conjugated drugs, folate-conjugated nanoparticles containing drugs or genetic material, and via chimeric antigen receptor (CAR) T cells. With respect to antifolates, several drugs inhibiting key enzymes in folate metabolisms, e.g., dihydrofolate reductase (DHF), thymidylate synthase (TS), and glycaminide ribonucleotide formyltransferase (GARTFase) [87], were evaluated for FR-targeting and anti-arthritic activity in vitro or in arthritic animals. In general, FR has a low affinity for DHFR inhibitors, including MTX, as compared with TS and GARTFase inhibitors [68, 81]. Antifolates with selectivity for FRα and FRβ rather than other folate transporters (RFC or PCFT) include BGC-945 and

| Category                                      | Remarks                                                                 | Reference |
|-----------------------------------------------|-------------------------------------------------------------------------|-----------|
| Antifolates                                   |                                                                         |           |
| MTX                                           | DHFR inhibitor, low FR affinity, high RFC/PCFT affinity                 | [102]     |
| CH-1504                                       | DHFR inhibitor, low FR affinity, high RFC affinity                      | [140]     |
| EC0746                                        | Aminopterin-folate conjugate DHFR inhibitor, activity in RA mouse model | [141]     |
| EC0746                                        | Aminopterin-folate conjugate DHFR inhibitor, activity in animal uveitis and encephalomyelitis model | [105]     |
| BGC945                                        | TS inhibitor, FRα/β specific                                            | [81, 142] |
| ALIMTA/pemetrexed                             | TS inhibitor, moderate FR affinity, high RFC/PCFT affinity              | [143]     |
| LY309887                                      | GARTFase inhibitor, high FR and RFC affinity, activity in mouse RA model | [144]     |
| LY329201 and LY309886                         | GARTFase inhibitors, in vitro activity, and activity in rat RA model    | [145]     |
| Divers compounds                              | GARTFase inhibitors, FRβ selective, in vitro activity                  | [146]     |
| Immunotoxins                                  |                                                                         |           |
| Anti-FRβ-PE38                                 | Recombinant immunotoxin dsFv anti-FRβ-Pseudomonas endotoxin A (PE38), Reduction RA synovial macrophages and fibroblasts | [147–149] |
| Anti-FRβ-PE38                                 | Targeting FRβ-positive tumor-associated macrophages in mouse glioma    | [150]     |
| Anti-FRβ-PE38                                 | Targeting FRβ-positive macrophages mouse atherosclerotic lesions        | [151]     |
| Folate-conjugated nanoparticles               |                                                                         |           |
| G5 dendrimer MTX                              | Targeting mouse primary FRβ macrophages                                | [152]     |
| Liposomes + MTX                               | Activity to FRβ-positive macrophages in mouse collagen-induced arthritis| [153]     |
| Dextran-MTX                                   | Activity to FRβ-positive macrophages in mouse collagen-induced arthritis| [154]     |
| Liposomes + anti-inflammatory drugs           | Targeting activated macrophages in inflammatory diseases              | [155]     |
| NFkB decoy                                    | Delivery to murine macrophages                                         | [156]     |
| G5 dendrimers MTX                             | Targeting FRβ-positive tumor-associated macrophages                    | [157]     |
| Liposomes + zoledronate                       | Targeting FRβ-positive tumor-associated macrophages                    | [158]     |
| HSA-nanodrug                                  | Targeting FRβ-positive AML cells                                      | [159]     |
| Liposomes + Dox                               | Targeting FRβ-positive AML cells                                      | [160]     |
| Folate drug conjugates                        |                                                                         |           |
| FA-Everolimus (EC0565)                        | Targeting FRβ-positive rat macrophages                                 | [161]     |
| FDG-FA                                        | Targeting FRα-positive tumors and FRβ-positive macrophages            | [162]     |
| Gene delivery (miRNA, siRNA)                  |                                                                         |           |
| FA-liposomes +MCL1-siRNA                      | Delivery to activated macrophages                                     | [163]     |
| FA-micelles/hydrogels                         | Gene delivery to activated macrophages                                | [164]     |
| FolamiRs                                      | FA-conjugated microRNAs for delivery to FR-positive cells             | [165]     |
| CAR T cells                                   |                                                                         |           |
| High affinity FRβ-specific CAR T cells        | For eradication FRβ-positive AML cells                                 | [166, 167]|

Table 3 FRβ therapeutic targeting in rheumatoid arthritis
selected GARTFase inhibitors. As illustrated in Table 3, folic acid conjugation to a variety of (anti-inflammatory) drugs, drug-containing liposomes, proteins, siRNAs, and miRNAs provided a bona fide vehicle for targeted delivery to FR-positive tumor cells and activated macrophages in different autoimmune inflammatory animal models. CAR T cell therapies with T cells transduced with a high affinity FRβ-specific single chain antibody represent a novel approach for selective targeting and lysis of FRβ-positive AML cells [166, 167]. Experimental therapeutics with anti-FRβ CAR T cells has as yet not been explored in relation to FRβ-positive macrophages targeting in auto-immune inflammatory diseases.

Although studies described in Table 3 underscore the suitability of macrophage FRβ targeting and imaging in RA models, several points may be considered to guide future research directions. One consideration relates to the choice of the RA animal model. For most anti-rheumatic drugs, it takes time to evaluate their action on arthritis activity when using synovial macrophage infiltration as a biomarker. Therefore, especially in the case of (sub)clinical arthritis, most existing animal models of RA may not be optimal from this perspective as they are either short-term acute models or models with severe bone destruction and/or poly-articular distribution [168, 169]. Instead, for (sub)clinical arthritis studies, antigen-induced arthritis models may be more suitable as they are more chronic and resemble human RA in terms of synovial macrophage infiltration and moderate systemic inflammation [44]. Also regarding animal studies, it is well documented that plasma levels of naturally circulating folates in rodents are 10-fold higher than in humans (≈ 100 nM vs 10 nM, respectively) [44, 170], which may increase competitive binding with an experimental folate-conjugated drug for FRβ. Lastly, FRβ expression and folate binding capacity is very much dependent on the activation status of macrophages [80], which may vary between animal models and stages of disease progression.

Optimal FRβ targeting will also benefit from information about receptor density, occupancy and kinetics (recycling rates), and levels of co-expression of any other folate transporters on target cells. In target cells with dual expression of RFC and FR, the first transporter is often dominant in internalizing natural folates and small molecule antifolates. FR can fully compensate for this when RFC expression/activity is low [171]. Since RFC, in contrast to FR, has a poor affinity for folic acid drug conjugates, FR is their sole route of cell entry and thus receptor density and recycling rates determine intracellular drug delivery to concentrations eliciting a therapeutic effect [74, 172].

Conclusion

There is growing evidence that FRβ expression on activated macrophages represent an important biomarker in various autoimmune inflammatory diseases, including RA. FRβ expression in relation to macrophage polarization warrants further investigations under conditions mimicking inflamed RA synovium. FRβ holds promise as a target for imaging with various modalities including PET and optical imaging with rationally designed tracers. This will allow disease monitoring studies and, ideally, early identification of arthritis and PET-guided therapy response monitoring. With respect to therapy, FRβ serves as an excellent target for delivery of therapeutics to macrophages; these may include folate antagonist and folate-conjugated drugs.

In conclusion, FRβ expression on activated macrophages may be exploited to guide future diagnostics, targeted therapies, and therapy response monitoring in RA.

Funding information

This study was supported by the Center for Translational Molecular Medicine (CTMM; project - TRACER), VU University Medical Center - Cancer Center Amsterdam (CCA—PV13/87), the Dutch Arthritis Association (NRF 09-01-404), and ZonMW translational project (Positron Emission Tomography and macrophage targeting to select individuals at risk for rheumatoid arthritis; 95104012).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Abbreviations

CD, cluster of differentiation; CTLA4, cytotoxic T lymphocyte antigen 4; DMARDs, disease-modifying anti-rheumatic drugs; FLS, fibroblast-like synoviocytes; FRβ, folate receptor β; GC, glucocorticoids; GPI, glycosylphosphatidylinositol; GM-CSF, granulocyte macrophage-colony-stimulating factor; HLA-DRB1, human leucocyte antigen DRB1; iNOS, inducible nitric oxide synthase; IL, interleukin; “M1-type” macrophage, pro-inflammatory macrophages; “M2-type” macrophages, anti-inflammatory macrophages; MLS, macrophage-like synoviocytes; M-CSF, macrophage-colony-stimulating factor; MTX, methotrexate; MRI, magnetic resonance imaging; NSAIDs, nonsteroidal anti-inflammatory drugs; PADI4, peptidyl arginine deaminase type 4; PET, positron emission tomography; PTPN22, protein tyrosine phosphatase, non-receptor type 22; RA, rheumatoid arthritis; SE, shared epitope; STAT4, signal transducer and activator of transcription 4; TGFβ, transforming growth factor β; TLR, toll-like receptor; TNFα, tumor necrosis factor α; TNFαP3, TNF alpha-induced protein 3

Open Access

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73:1316–22.
2. Klareskog L, Rönnelid J, Lundberg K, Padyukov L, Alfredsson L. Immunity to citrullinated proteins in rheumatoid arthritis. Annu Rev Immunol. 2008;26:651–75.
predict the clinical outcome of infliximab treatment of rheumatoid arthritis: an explorative study. J Nucl Med. 2011;52:77–80.

40. Goerres GW, Forster A, Uebelhart D, Seifert B, Treyer V, Michel B, et al. F-18 FDG whole-body PET for the assessment of disease activity in patients with rheumatoid arthritis. Clin Nucl Med. 2006;31:386–90.

41. Krogholler MA, Boellaard R, Elzinga EH, van der Laken CJ, Maruyama A, Kloe RT, et al. Quantification of [(11)C]PK11195 binding in rheumatoid arthritis. Eur J Nucl Med Mol Imaging. 2009;36:624–31.

42. Gent YY, Steiger M, Windhorst AD, Huisman MC, Kassouf M, et al. Promising potential of a new generation translocator protein tracer providing enhanced contrast of arthritis imaging by positron emission tomography in a rat model of arthritis. Arthritis Res Ther. 2014;16:R70.

43. van der Laken CJ, Elzinga EH, Kropholler MA, Molthoff CFM, van der Heijden JW, Maruyama K, et al. Noninvasive imaging of macrophages in rheumatoid synovitis using [(11)C]-(R)-PK11195 and positron emission tomography. Arthritis Rheum. 2008;58:3350–5.

44. Chandrupatla DM, Weijers K, Gent YYJ, van der Heijden JW, Maruyama K, et al. Evaluation of the novel folate receptor ligand [(18)F] fluoro-PEG-folate for macrophage targeting in a rat model of arthritis. Arthritis Res Ther. 2010;12:R37.

45. Chauveau F, Boutin H, Van Camp N, Dolle F, Tavitian B. Nuclear imaging of neuroinflammation: a comprehensive review of [(11)C]PK11195 challengers. Eur J Nucl Med Mol Imaging. 2008;35:2304–19.

46. James ML, Fulton RR, Henderson DJ, Beller S, Meikle SR, Thomas S, et al. Synthesis and in vivo evaluation of a novel peripheral benzodiazepine receptor PET radioligand. Bioorg Med Chem. 2005;13:6188–94.

47. James ML, Fulton RR, Verschuer J, Henderson DJ, Garreau L, Chalon S, et al. HDU-714, a novel translocator protein-specific ligand: synthesis, radiofluorination, and pharmacologic characterization. J Nucl Med. 2008;49:814–22.

48. Gent YYJ, Weijers K, Molthoff CFM, Windhorst AD, Huisman MC, Smith DE, et al. Evaluation of the novel folate receptor ligand [(18)F] fluoro-PEG-folate for macrophage targeting in a rat model of arthritis. Arthritis Res Ther. 2013;15:R37.

49. Chandrupatla DM, Jansen G, Vos R, Verlaan M, Chen Q, Low PS, et al. In vivo monitoring of anti-folate therapy in arthritic rats using [(18)F]fluoro-PEG-folate and positron emission tomography. Arthritis Res Ther. 2013;15:R37.

50. Chandrupatla DM, Jansen G, Mantel E, Low PS, Matsuyama T, Musters R, et al. Imaging and methotrexate response monitoring of systemic inflammation in arthritic rats employing the macrophage PET tracer [18F]fluoro-PEG-folate. Contrast Media Mol Imaging. 2018;2018:8092781.

51. Narayan N, Owen D, Mandhair H, Smyth E, Carlucci F, Saleem A, et al. Translocator protein as an imaging marker of macrophage and stromal activation in RA pannus. J Nucl Med. 2018;59:1125–32.

52. Papadopoulos V, Baraldi M, Guilarte TR, Knuusen TB, Lacapere J-J, Lindemann P, et al. Translocator protein (18kDa): synthesis, radiofluorination, and pharmacologic characterization. J Nucl Med. 2017;58:11086–91.

53. Nozaki S, Kashiwagi A, Kashiwagi T, Suzuki S, Goto M, Mawatari A, Nakatani Y, et al. Development of diagnostic techniques for early rheumatoid arthritis using positron emission tomography with [(11)C]PK11195 and [(11)C]ketoprofen tracers. Mol Imaging Biol. 2017;19:746–53.

54. Folkersma H, Foster Dingley JC, van Berckel BNM, Zeremluver A, Boellaard R, Huisman MC, et al. Increased cerebral [(R)-[(11)C]PK11195 uptake and glutamate release in a rat model of traumatic brain injury: a longitudinal pilot study. J Neuroinflammation. 2011;8:67.

55. Chauveau F, Van Camp N, Dolle F, Kuhnast B, Hinnen F, Damott A, et al. Comparative evaluation of the translocator protein radioligands 11C-DPA-713, 18F-DPA-714, and 11C-PK11195 in a rat model of acute neuroinflammation. J Nucl Med. 2009;50:468–76.

56. Doorduin J, Klein HC, Diercks RA, James M, Kassouf M, de Vries EFJ. [11C]-DPA-713 and [18F]-DPA-714 as new PET tracers for TSPO: a comparison with [11C]-PK-11195 in a rat model of herpes encephalitis. Mol Imaging Biol. 2009;11:386–98.

57. Vivasch L, O’Brien TJ. Imaging microglial activation with TSPO PET: lighting up neurologic diseases? J Nucl Med. 2016;57:165–8.

58. Narayan N, Owen DR, Taylor PC. Advances in positron emission tomography for the imaging of rheumatoid arthritis. Rheumatology (Oxford). 2017;56:1837–46.

59. Pottier G, Bernards N, Dollé F, Boisgard R. [(18)F]DPA-714 as a biomarker for positron emission tomography imaging of rheumatoid arthritis in an animal model. Arthritis Res Ther. 2014;16:R69.

60. Trelon C, Largeau B, Ribeiro MJS, Guilloteau D, Dupont AC, Arlicot N. Molecular targets for PET imaging of activated microglia: the current situation and future expectations. Int J Mol Sci. 2017;18.

61. Low PS, Hemne WA, Doornweerd DD. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem Res. 2008;41:120–9.

62. Yi YS. Folate receptor-targeted diagnostics and therapeutics for inflammatory diseases. Immune Netw. 2016;16:337–43.

63. Elbakat H, Ratnam M. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev. 2004;56:1067–84.

64. Gonen N, Assaraf YG. Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist Updat. 2012;15:183–210.

65. Assaraf YG, Leamon CP, Reddy JA. The folate receptor as a rational therapeutic target for personalized cancer treatment. Drug Resist Updat. 2014;17:89–95.

66. Jansen G, Peters GJ. Novel insights in folate receptors and transporters: implications for disease and treatment of immune diseases and cancer. Pteridines. 2015;26:41–53.

67. Mathery LH, Hou Z, Gangjee A. The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeu- tic targeting of cancer. Cancer Chemother Pharmacol. 2017;81:1–15.

68. Westerhof GR, Schornagel JH, Kathmann I, Jackman AL, Rosowsky A, Forsh R, et al. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity. Mol Pharmacol. 1995;48:459–71.

69. Wu M, Fan J, Gunning W, Ratnam M. Clustering of GPI-anchored folate receptor independent of both cross-linking and association with caveolin. J Membr Biol. 1997;159:137–47.

70. Shen F, Wu M, Ross JF, Miller D, Ratnam M. Folate receptor type γ is primarily a secretory protein due to lack of an efficient signal for glycosylphosphatidylinositol modification: protein characterization and cell type specificity. Biochemistry. 1995;34:5660–5.

71. Maziarz KM, Monaco HL, Shen F, Ratnam M. Complete mapping of divergent amino acids responsible for differential ligand binding of folate receptors alpha and beta. J Biol Chem. 1999;274:11086–91.

72. Wibowo AS, Singh M, Reeder KM, Carter JJ, Kovach AR, Meng W, et al. Structures of human folate receptors reveal biological trafficking states and diversity in folate and antifolate recognition. Proc Natl Acad Sci. 2013;110:15180–8.
73. Rijnboutt S, Jansen G, Posthuma G, Hynes JB, Schornagel JH, Strous GJ. Endocytosis of GPI-linked membrane folate receptor-α. J Cell Biol. 1996;132:35–47.
74. Varghese B, Vlashi E, Xia W, Ayala Lopez W, Paulos CM, Reddy J, et al. Folate receptor-β in activated macrophages: ligand binding and receptor recycling kinetics. Mol Pharm. 2014;11:3609–16.
75. Anderson RG, Kamen BA, Rothberg KG, Lacey SW. Pocyteos: sequestration and transport of small molecules by caveolae. Science. 1992;255:410–1.
76. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem. 2005;338:284–93.
77. Ross JF, Wang H, Behm FG, Mathew P, Wu M, Booth R, et al. Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer. 1999;85:348–57.
78. Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Cancer 1994;2432–43.
79. Shen J, Hilgenbrink AR, Xia W, Feng Y, Dimitrov DS, Reddy J, et al. Folate receptor-β constitutes a marker for human proinflammatory monocytes. J Leukoc Biol. 2014;96:563–70.
80. Xia W, Hilgenbrink AR, Matteson EL, Lockwood MB, Cheng JX, Low PS. A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages. Blood. 2009;113:438–46.
81. van der Heijden JW, Oerlemans R, Jansen G, Posthuma G, Hynes JB, Schornagel JH, et al. Synovial lining, endothelial and inflammatory mononuclear cells are polarization-dependent in vitro and in vivo and are regulated by activin. J Leukoc Biol. 2014;95:1567–73.
82. Shen J, Putt KS, Visscher DW, Murphy L, Cohen C, Singhal S, et al. Assessment of folate receptor-β expression in human neoplastic tissues. Oncotarget. 2015;6:14700–9.
83. Wang H, Zheng X, Behm FG, Mathew P, Wu M, Booth R, et al. Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer. 1999;85:348–57.
84. Qi H, Ratnam M. Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: mechanism and utility in enhancing selective growth inhibition by antifolates. Cancer Res. 2006;66:5875–82.
85. Dhanasekaran S, Biswal BK, Sumantran VN, Verma RS. Augmented sensitivity to methotrexate by curcumin induced overexpression of folate receptor in KG-1 cells. Biochemie. 2013;95:1567–73.
86. Samaniego R, Palacios BS, Dominguez-Soto A, Vidal C, Salas A, Matsuys T, et al. Macrophage uptake and accumulation of folates are polarization-dependent in vitro and in vivo and are regulated by activin. J Leukoc Biol. 2014;95:797–808.
87. Blits M, Jansen G, Assaraf YG, Van De Wiel MA, Lems WF, Nurmohamed MT, et al. Methotrexate normalizes up-regulated folate pathway genes in rheumatoid arthritis. Arthritis Rheum. 2013;65:2791–802.
88. van der Heijden JW, Assaraf YG, Gerards AH, Oerlemans R, Lems WF, Scheper RJ, et al. Methotrexate analogues display enhanced inhibition of TNF-α production in whole blood from RA patients. Scand J Rheumatol. 2014;43:9–16.
89. Municio C, Soler Palacios B, Estrada-Capetillo L, Benguria A, Dopazo A, Garcia-Lorenzo E, et al. Methotrexate selectively targets human proinflammatory macrophages through a thymidylate synthase/p53 axis. Ann Rheum Dis. 2016;75:2157–65.
90. Ceponis A, Konttinen YT, Imai S, Tamulahtieni M, Li TF, Xu JW, et al. Synovial lining, endothelial and inflammatory mononuclear cell proliferation in synovial membranes in psoriatic and reactive arthritis: a comparative quantitative morphometric study. Br J Rheumatol. 1998;37:170–8.
91. Lalor PA, Mapp PI, Hall PA, Revell PA. Proliferative activity of cells in the synovium as demonstrated by a monoclonal antibody, Ki67. Rheumatol Int. 1987;7:183–6.
92. Brown PM, Prat AG, Isacis JD. Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nat Rev Rheumatol. 2016;12:731–42.
93. Machacek C, Supper V, Leksa V, Milutovic G, Spittler A, Drbal K, et al. Folate receptor beta regulates integrin CD11b/CD18 adhesion of a macrophage subset to collagen. J Immunol. 2016;197:2229–38.
94. Ayala-Lopez W, Xia W, Varghese B, Low PS. Imaging of atherosclerosis in apolipoprotein E knockout mice: targeting of a folate-conjugated radiopharmaceutical to activated macrophages. J Nucl Med. 2010;51:768–74.
95. Jager NA, Westra J, Golestani R, van Dam GM, Low PS, Tio RA, et al. Folate receptor-β imaging using 99mTc-folate to explore distribution of polarized macrophage populations in human atherosclerotic plaque. J Nucl Med. 2014;55:1945–51.
96. Winkel LCI, Groen HC, van Thiel BS, Muller C, van der Steen, AFW, Wentzel JJ, de Jong M, Van der Heiden K. Folate receptor-targeted single-photon emission computed tomography/computed tomography to detect activated macrophages in atherosclerosis: can it distinguish vulnerable from stable atherosclerotic plaques? Mol Imaging 2014;13.
97. Muller A, Beek K, Rancic Z, Muller C, Fischer CR, Betzel T, et al. Imaging atherosclerotic plaque inflammation via folate receptor targeting using a novel 18F-folate radiotracer. Mol Imaging. 2014;13:1–11.
98. O’Shannessy DJ, Somers EB, Wang LC, Wang H, Hsu R. Expression of folate receptors alpha and beta in normal and cancerous gynecologic tissues: correlation of expression of the beta isoform with macrophage markers. J Ovarian Res. 2015;8:1–9.
99. Kurahara H, Takao S, Kuwahata T, Nagai T, Ding Q, Maeda K, et al. Clinical significance of folate receptor b-expressing tumor-associated macrophages in pancreatic cancer. Ann Surg Oncol. 2012;19:2264–71.
100. Shen J, Hu Y, Putt KS, Singhal S, Han H, Visscher DW, et al. Assessment of folate receptor alpha and beta expression in selection of lung and pancreatic cancer patients for receptor targeted therapies. Oncotarget. 2017;9:4485–95.
101. Haverkamp JM, Craet SA, Elzeey BD, Cimeno C, Ratlliff TL. In vivo suppressive function of myeloid-derived suppressor cells is limited to the inflammatory site. Eur J Immunol. 2011;41:749–59.
102. Nakashima-Matsushita N, Homma T, Yu S, Matsuda T, Sunahara N, Nakamura T, et al. Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum. 1999;42:1609–16.
103. Albano-Aluquin S, Malyss J, Aluquin VR, Ratnam M, Olsen N. An immunohistochemical analysis of folate receptor beta expression and distribution in giant cell arteritis - a pilot study. Am J Clin Exp Immunol. 2017;6:107–14.
104. Varghese B, Haase N, Low PS. Depletion of folate-receptor-positive macrophages leads to alleviation of symptoms and prolonged survival in two murine models of systemic lupus erythematosus. Mol Pharm. 2007;4:675–85.
105. Lu Y, Wollak KN, Cross VA, Westrick E, Wheeler LW, Stinnette AFW, Wentzel JJ, de Jong M, Van der Heiden K. Folate receptor-targeted single-photon emission computed tomography/computed tomography to detect activated macrophages in atherosclerosis: can it distinguish vulnerable from stable atherosclerotic plaques? Mol Imaging 2014;13.
106. Siebelt M, Korthagen N, Wei W, Groen H, Bastiaansen-Jenniskens Y, Muller C, et al. Triamcinolone acetate activates...
an anti-inflammatory and folate receptor-positive macrophage that prevents osteophytosis in vivo. Arthritis Res Ther. 2015;17:1–13.

107. Piscara TM, Müller C, Mindt TL, Lubberts E, Verhaar J, Krenning EP, et al. Imaging of activated macrophages in experimental osteoarthritis using folate-targeted animal single-photon-emission computed tomography/computed tomography. Arthritis Rheum. 2011;63:1898–907.

108. Wang N, Liang H, Zen K. Molecular mechanisms that influence the macrophage M1-M2 polarization balance. Front Immunol. 2014;5:1–9.

109. Murray P, Allen J, Biswas S, Fisher E, Gilroy D, Goerdt S, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014;17:14–20.

110. Ambarus CA, Krausz S, van Eijk M, Radstake TR, Reedquist KA, et al. Systematic validation of specific phenotypic markers for in vitro polarized human macrophages. J Immunol Methods. 2012;375:196–206.

111. Kittan NA, Allen RM, Dhaliwal A, Cavassani KA, Schaller M, Gallagher KA. Cytokine induced phenotypic and epigenetic signatures are key to establishing specific macrophage phenotypes. PLoS One. 2013;8:1–15.

112. Ambarus CA, Noordenbos T, de Hair MJ, Tak PP, Baeten DL. The macrophage M1-M2 polarization balance. Front Immunol. 2014;5:14874.

113. Gottfried E, Kunz-Schughart LA, Weber A, Rehli M, Peuker A, Müller A, et al. Expression of CD68 in non-myeloid cell types. Scand J Immunol. 2008;67:453–63.

114. Crocker PR, Gordon S. Properties and distribution of a lectin-like hemagglutinin differentially expressed by murine stromal tissue macrophages. J Exp Med. 1986;164:1862–75.

115. Hemstra IH, Beijer MR, Veninga H, Vrijland K, Borg EGF, Oliver BJ, et al. The identification and developmental requirements of colonic CD169+ macrophages. Immunology. 2014;142:403–9.

116. York MR, Ni T, Mangini AJ, Lemaire R, Van Seventer JM, Layfatis R. A macrophage marker, siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferon and toll-like receptor agonists. Arthritis Rheum. 2007;56:1010–20.

117. Puig-Kröger A, Sierra-Filardi E, Dominguez-Soto A, Samaniego LF, Escribano R, Arrobas-Gonzalez AL, et al. Folate receptor β is expressed by tumor-associated macrophages and constitutes a marker for M2 anti-inflammatory/ regulatory macrophages. J Immunol. 2009;183:17–26.

118. Palacios BS, Estrada-Capetillo L, Quiroz E, Criado G, Nieto C, et al. Synthesis and preclinical evaluation of folate-NOTA-Al 18F for PET imaging of folate receptor-positive tumors. Mol Pharm. 2016;13:1520–7.

119. Van Dam GM, Themelis G, Crane LMA, Harlaar NJ, Pleijhuis RG, Kelder W. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in human results. Nat Med. 2011;17:1315–9.

120. Zheng X, Xie D, Zhou F, Xu B, Chen W, Chen WR. Indocyanine green-containing nanostructure as near infrared dual-functional targeting probes for optical imaging and photothermal therapy. Mol Pharm. 2011;8:447–56.

121. Snoeks TJA, Van Driel PBAA, Keereweer S, Aime S, Brindle KM, van Dam GM, et al. Towards a successful clinical implementation of fluorescence-guided surgery. Mol Imaging Biol. 2014;16:147–51.

122. Sun YJ, Shen J, Thibodeaux J, Huang G, Wang Y, Gao J, et al. In vivo optical imaging of folate receptor-beta in head and neck squamous cell carcinoma. Laryngoscope. 2014;124:E312–9.

123. Boogerd LSF, Hoogstins CES, Gaarenstroom KN, de Kroon CD, Beltman JJ, Bosse T, et al. Folate receptor-α targeted near-infrared fluorescence imaging in high-risk endometrial cancer patients: a tissue microarray and clinical feasibility study. Oncotarget. 2018;9:791–801.

124. Kelderhouse LE, Mahalingam S, Low PS. Predicting response to therapy for autoimmune and inflammatory diseases using a folate receptor-targeted near-infrared fluorescent imaging agent. Mol Imaging Biol. 2016;18:201–8.

125. Szoln M, Lin SL, Bermudes D, Zheng L, King I, Kirn D. Advances in synergistic combinations of Chinese herbal medicine for the treatment of cancer. Current Cancer Drug Target. 2000;105:1027–30.

126. Nogueira E, Gomes AC, Preto A, Cavaco-Paulo A. Folate-targeted nanoparticles for rheumatoid arthritis therapy. Nanomedicine. 2016;12:1113–26.
